Compare CGEM & ESRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CGEM | ESRT |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 904.7M | 913.4M |
| IPO Year | 2020 | 2012 |
| Metric | CGEM | ESRT |
|---|---|---|
| Price | $16.19 | $5.58 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 3 |
| Target Price | ★ $30.13 | $6.35 |
| AVG Volume (30 Days) | 739.9K | ★ 1.3M |
| Earning Date | 05-11-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 2.49% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $768,270,000.00 |
| Revenue This Year | N/A | $4.26 |
| Revenue Next Year | $5.20 | $1.52 |
| P/E Ratio | ★ N/A | $552.50 |
| Revenue Growth | N/A | ★ 0.05 |
| 52 Week Low | $5.68 | $4.87 |
| 52 Week High | $16.74 | $8.76 |
| Indicator | CGEM | ESRT |
|---|---|---|
| Relative Strength Index (RSI) | 64.56 | 52.76 |
| Support Level | $11.92 | $5.35 |
| Resistance Level | $16.10 | $7.04 |
| Average True Range (ATR) | 1.04 | 0.19 |
| MACD | 0.19 | -0.00 |
| Stochastic Oscillator | 96.86 | 54.55 |
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Empire State Realty Trust Inc is a real estate investment trust (REIT) that owns and operates office, retail, and multifamily properties located in New York City, prominently in Manhattan. Its portfolio includes office and retail space as well as residential units. The company's objective is to maximize cash flow and total returns to its shareholders and to increase the value of the properties. Its reportable segments consist of a real estate segment and an Observatory segment. The majority of revenue is derived from the Real Estate segment, which includes all activities related to the ownership, management, operation, acquisition, redevelopment, repositioning and disposition of its traditional real estate assets.